Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women at least 18 years of age who are recipients of a kidney transplant between 3 months and 5 years before the screening date~* Patients taking oral Prograf® capsules twice daily, at least 2 mg total dose per day, as part of their maintenance immunosuppression therapy, with tacrolimus trough levels of 5 to 15 ng/mL~* Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days before receiving study drug~Exclusion Criteria:~* Recipients of any transplanted organ other than kidney~* Recipients of a bone marrow transplant~* Patients with an eGFR (MDRD7) \< 30 mL/min at Screening~* Patients with a spot protein:creatinine ratio \> 0.5~* Patients with a WBC count ≤ 2.8 ´ 109/L unless the WBC count has been stable for at least 2 weeks and the absolute neutrophil count is \> 1.0 ´ 109 /L~* Patients unable to swallow study medication~* Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent and who are unwilling or unable to comply with the study protocol requirements~* Pregnant or nursing women~* Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception~* Patients who were treated with any other investigational agent within 3 months before Screening~* Patients who have taken sirolimus or everolimus within 3 months before Screening~* Patients on concurrent immunosuppression with MMF (CellCept) or MPS delayed-release tablets (Myfortic) who have not been on stable doses for at least 4 weeks before Screening~* Patients withdrawn from corticosteroids less than 30 days before Screening~* Patients with an episode of acute rejection requiring antibody therapy within 3 months before Screening~* Patients treated for acute rejection within 30 days before Screening~* Patients who are hepatitis C virus (HCV) negative who have received an HCV positive (HCV RNA by polymerase chain reaction or HCV antibody) donor kidney~* Patients seropositive for human immunodeficiency virus~* Patients with a current malignancy or a history of malignancy (within the past 5 years), except basal or nonmetastatic squamous cell carcinoma of the skin that has been treated successfully~* Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives~* Patients with severe diarrhea, vomiting, active peptic ulcer, or gastrointestinal disorder that may affect the absorption of tacrolimus~* Patients with any form of current substance abuse, psychiatric disorder, or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCP-Tacro (Type: EXPERIMENTAL): LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
- Prograf (tacrolimus) (Type: ACTIVE_COMPARATOR): Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)

Based on this trial design, predict the completion outcome and termination type (if applicable).